NewsHK
Centene Corporation has raised its 2026 adjusted earnings per share guidance to more than $4.80, reflecting faster-than-expected operating improvements in its Medicaid and Marketplace segments.
Management noted that roughly 50 cents per share of the 2026 earnings will not recur in 2027 due to prior-year settlements, setting a distinct hurdle for future profitability.
The company’s stock has surged 57% year to date, outperforming the S&P 500’s 14.7% gain and significantly ahead of peers UnitedHealth Group Incorporated and Elevance Health, Inc., which returned 14% and 14.2%, respectively.
This sharp rerating follows a difficult 2025, with investors now focused on whether recent margin gains can be sustained into 2027 rather than merely capturing recovery expectations.
Keep reading